Molcure, Boehringer Ingelheim Sign Multi-Year AI-Driven Antibody Discovery Agreement

Molcure Inc., a biotechnology firm specializing in artificial intelligence-based drug discovery, has entered into a multi-year strategic research agreement with Boehringer Ingelheim focused on the development of antibody therapeutics targeting multiple disease areas, leveraging Molcure’s proprietary AI platform.

The collaboration is designed to combine Molcure’s expertise in AI-driven antibody engineering with Boehringer Ingelheim’s capabilities in high-throughput experimentation. Molcure’s platform centers on a large language model (LLM) tailored for antibody design, which will be integrated with experimental data generated by Boehringer Ingelheim. The companies aim to use this hybrid approach—merging wet-lab results with in silico modeling—to identify novel antibody sequences that may be difficult to discover using conventional methods.

“We are delighted that Boehringer Ingelheim has chosen Molcure as a partner in recognition of our AI technology’s ability to deliver strong results from limited data,” said Satoshi Tamaki, CEO and CSO of Molcure Inc. “We are excited to work alongside Boehringer Ingelheim’s scientists to further evolve our innovative AI-driven antibody discovery platform and make a significant contribution to their drug discovery programs. I hope that our partnership will lead to new treatments that improve the prognosis and quality of life for patients around the world.”

The agreement aligns with Boehringer Ingelheim’s stated goal of advancing first-in-class therapies. By integrating AI and biological research, the companies aim to accelerate the development of next-generation antibody drugs.